FDA approval: Zenocutuzumab for NRG1+ NSCLC – IASLC

The International Association for the Study of Lung Cancer (IASLC) shared a post on X:

“ICYMI, the FDA recently approved zenocutuzumab for NSCLC with an NRG1 fusion.

Catch this all-new episode of Lung Cancer Considered as Stephen V Liu and Alison Schram discuss this breakthrough and what this approval means for treating NSCLC patients with an NRG1 fusion

Listen now.”